Aldevron News: Partnerships (3)

Aldevron to Provide New GMP Cas9 Nuclease Through Agreement with Integrated DNA Technologies

Aldevron and Integrated DNA Technologies, Inc. (IDT), a supplier of custom nucleic acid and genome editing products, have announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFiTM Cas9 Nuclease—which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.  

Read More

Aldevron Manufactures Malaria DNA Vaccine for Naval Medical Research Center

Today, at the State of Technology Conference with Senator Hoeven and the Fargo Moorhead West Fargo Chamber of Commerce, Aldevron announces completing the production of a DNA-based vaccine to combat malaria under a contract with the Naval Medical Research Center (NMRC).  Aldevron, a leading contract manufacturer of plasmid DNA, proteins, and antibodies, produced three plasmid DNA constructs that have been delivered to NMRC in preparation for a phase I/II challenge study.

Read More